Skip to main content
SpringerLink
Log in

Rituximab non-inferior to TNFi and cost saving for RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Optimal Management of patients with rheumatoid arthritis who Require Biologic Therapy

  2. 28 joint count disease activity score

  3. 2014 British pounds

References

  1. Porter D et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial Lancet : 17 May 2016. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(16)00380-9

    Google Scholar 

  2. Huizinga TWJ, et al. Drivers of costly treatment strategies in rheumatoid arthritis. Lancet : 17 May 2016. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(16)30548-7

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rituximab non-inferior to TNFi and cost saving for RA. PharmacoEcon Outcomes News 753, 28 (2016). https://doi.org/10.1007/s40274-016-3061-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3061-x

Search

Navigation